We are live on ! Find out more
LSBPW

LakeShore Biopharma Warrants
LSBPW

Delisted

LSBPW was delisted on the 19th of September, 2025.

Back to rankings

2 hedge funds and large institutions have $18 invested in LakeShore Biopharma Warrants in 2026 Q1 according to their latest regulatory filings, with funds opening new positions, increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% less funds holding

Funds holding: 3 → 2 (-1)

64% less capital invested

Capital invested by funds: $50 → $18 (-$32)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
2
Holders Change
-1
Holders Change %
-33.33%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
HIM
HGC Investment Management
Ontario, Canada
-$35
Name Holding Trade Value Shares
Change 		Change in
Stake
AA
1
Ancora Advisors
Ohio
$18 – – –
HIM
2
HGC Investment Management
Ontario, Canada
– -$35 -5,000 Closed

LSBPW Hedge Fund Activity: Q1 2026 in Review

2 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in LakeShore Biopharma Warrants (LSBPW) for Q1 2026, worth a combined $18 — down 64% from $50 a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of LSBPW and 0 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was HGC Investment Management, exiting entirely with an estimated $35 sold.

  • 2 institutional investors held LakeShore Biopharma Warrants (LSBPW) as of Q1 2026, down from 3 in Q4 2025.
  • Funds reported $18 of LakeShore Biopharma Warrants stock for Q1 2026, down 64% quarter-over-quarter.
  • 0 funds opened new LakeShore Biopharma Warrants positions in Q1 2026 and 1 closed out, a net change of -1 holder.
  • The largest LakeShore Biopharma Warrants seller in Q1 2026 was HGC Investment Management, an estimated $35 sold.

Based on aggregated 13F filings for Q1 2026.